ImmunityBio, Inc.
IBRX
$8.77
$0.566.76%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 20.43% | 20.28% | |||
| Total Other Revenue | -95.37% | 6,925.00% | |||
| Total Revenue | 19.41% | 21.33% | |||
| Cost of Revenue | 115.82% | 30.15% | |||
| Gross Profit | 18.88% | 21.28% | |||
| SG&A Expenses | -5.49% | -13.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.42% | -10.25% | |||
| Operating Income | -16.27% | 21.96% | |||
| Income Before Tax | 7.75% | 27.08% | |||
| Income Tax Expenses | -285.71% | -113.01% | |||
| Earnings from Continuing Operations | 7.90% | 27.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -33.33% | 10.53% | |||
| Net Income | 7.89% | 27.34% | |||
| EBIT | -16.27% | 21.96% | |||
| EBITDA | -17.88% | 23.33% | |||
| EPS Basic | 11.83% | 31.86% | |||
| Normalized Basic EPS | 11.71% | 31.59% | |||
| EPS Diluted | 10.70% | 31.86% | |||
| Normalized Diluted EPS | 11.71% | 31.59% | |||
| Average Basic Shares Outstanding | 4.55% | 6.57% | |||
| Average Diluted Shares Outstanding | 4.55% | 6.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||